Activating mutations of KRAS and BRAF are commonly occurred in CRC and have been identified as predictors of resistance to EGFR monoclonal antibodies such as cetuximab and were associated with poor survival (Bertotti et al., 2015; De Roock et al., 2010). The gene discussed is BRAF; the disease is colorectal carcinoma.